

# The COVAX Facility and the AMC DCVMN Annual General Meeting

Seth Berkley, Gavi  
4<sup>th</sup> November 2020

# Our goals

To support the largest actively managed portfolio of vaccine candidates globally

To deliver 2 billion doses by end of 2021

To offer a compelling return on investment by delivering COVID-19 vaccines as quickly as possible

To guarantee fair and equitable access to COVID-19 vaccines for all participants

To end the acute phase of the pandemic by the end of 2021

*Thank you DCVMN companies as a key partner in this endeavor*



# COVAX Facility focused on transparency, global access and impact

Bold ideas and brilliant innovation for the worst global health crisis in 100 years

## Pooled demand



Consolidates buying power and provides participants access to a broad and actively-managed portfolio



The COVAX Facility



## Pooled supply



Provides manufacturers access to a massive, demand-assured market

# The COVAX Facility serves all participants

The COVAX AMC is an instrument for ODA-eligible countries

For all participants

The COVAX Facility

The AMC 92  
*ODA supported*

For ODA-eligible participants

# The Gavi Board endorsed the eligibility of 92 countries and economies for support through the COVAX AMC

**Low income**: Afghanistan, Benin, Burkina Faso, Burundi, Central African Republic, Chad, Congo, Dem. Rep., Eritrea, Ethiopia, Gambia, The Guinea, Guinea-Bissau, Haiti, Korea, Dem. People's Rep., Liberia, Madagascar, Malawi, Mali, Mozambique, Nepal, Niger, Rwanda, Sierra Leone, Somalia, South Sudan, Syrian Arab Republic, Tajikistan, Tanzania, Togo, Uganda, Yemen, Rep.,

**Lower-middle income**: Angola, Algeria, Bangladesh, Bhutan, Bolivia, Cabo Verde, Cambodia, Cameroon, Comoros, Congo, Rep. Côte d'Ivoire, Djibouti, Egypt, Arab Rep., El Salvador, Eswatini, Ghana, Honduras, India, Indonesia, Kenya, Kiribati, Kyrgyz Republic, Lao PDR, Lesotho, Mauritania, Micronesia, Fed. Sts., Moldova, Mongolia, Morocco, Myanmar, Nicaragua, Nigeria, Pakistan, Papua New Guinea, Philippines, São Tomé and Príncipe, Senegal, Solomon Islands, Sri Lanka, Sudan, Timor-Leste, Tunisia, Ukraine, Uzbekistan, Vanuatu, Vietnam, West Bank and Gaza, Zambia, Zimbabwe

**Additional IDA eligible**: Dominica, Fiji, Grenada, Guyana, Kosovo, Maldives, Marshall Islands, Samoa, St. Lucia, St. Vincent and the Grenadines, Tonga, Tuvalu.

*Based on 2018 and 2019 World Bank GNI data.*

# Additional vaccine support will be provided to the AMC 92 group and tailored to individual health systems



## LICs, LMICs and IDA-eligible UMICs

### Vaccine Access (COVAX Facility)

---

- Financial support for vaccine procurement and access through the COVAX AMC

### Procurement mechanisms

---

- Support from the Alliance through UNICEF and other mechanisms e.g. PAHO Revolving Fund

### Delivery

---

- Support for cold chain equipment and technical assistance

- 
- **Support may be differentiated within the group.** All options explored will aim to ensure that participants do not face any significant barriers to accessing a COVID-19 vaccine

# At the end of September, the Gavi Board approved several decisions in relation to support to the 92 AMC economies

1 With regards to the **COVAX facility and access to vaccine** the Board took the following decisions:

- **Approved** the interim Terms and Conditions (T&Cs) for AMC and self-financing countries;
- **Approved** the proposal for vaccine cost-sharing up to \$1.60-2.00 / dose, with a goal of mobilising resources from multilateral development banks, and noting that inability to meet cost-sharing will not prevent or delay provision of doses
- **Requested** the Secretariat to return in December with a proposal for vaccine and delivery support to India under COVAX AMC92

2 With regards to **delivery support** for the 92 COVAX AMC economies:

- **Approved** the allocation of \$150M of Gavi core resources to be made available for CCE and TA support to the 56 Gavi-eligible countries and India (priority), as well as additional AMC92 economies on a case-by-case basis.
- **Noted** the proposed approach to not invest in at-scale deployment of UCC equipment at this time, while supporting the Secretariat continuing to explore mitigation strategies

# 61 Self Financing Participants & Team Europe join the 92 AMC participants for a total of 182 participants

representing over >80 % of the world's population

	Number of participants
Fully Self-Financing	90
AMC92	92
Total	182



# Countries, R&D and manufacturers

**Higher Income Economies: 90**

Commitment Agreements (61) + team  
Europe (29)

**LIC/LMIC: 92 AMC-eligible economies**

**R&D: 9 CEPI-supported candidates, 9 BMGF-  
supported candidates under evaluation, and  
procurement conversations ongoing with additional  
producers**

**Manufacturers: 13 vaccine manufacturers across  
Asia, Europe and S. America <sup>2</sup>**

# For most economies COVAX represents lower risks and costs

- **Early vaccines** - COVAX has confirmed manufacturing capacity is available sufficient for up to 2B doses of vaccine by 2021 amidst intense competition
- **Likely lower cost** - COVAX is negotiating at scale for better terms
- **Diversified portfolio of candidates** – a portfolio of 9+ vaccines increases chances of development success and preferred vaccine characteristics
- **Safe and efficacious vaccines** – Only vaccines that have undergone rigorous WHO or SRA approval processes will be distributed by COVAX
- **Support beyond vaccines** – Potential support to distribute and deliver vaccines

# COVAX timelines leading to first vaccine shipments

## July 2020

First economy engagements on COVAX Facility introduction

Board confirmed AMC 92 countries

## Sept 2020

COVAX AMC Q&A disseminated

COVAX AMC 92 briefings

Board confirms design and delivery support

## Oct 2020

AMC 92 briefing: Guidance on COVAX-related application processes

SAGE guidance on risk group prioritization

First procurement bid requests

## Nov 2020

COVAX-related application materials available and application window opens

## Dec 2020

Rolling submissions of COVAX-related application begin

AMC fundraising deadline for \$2bn urgent ask

## Jan-June 2021

Review and allocation decisions

First vaccine shipments go out

AMC fundraising by end 2021 ask of least \$5bn

# THANK YOU